- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02085018
Pilot Trial Of Omeprazole in Idiopathic Pulmonary Fibrosis (IPF) (PPIPF)
A Randomised, Placebo-controlled Trial of Omeprazole in Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic pulmonary fibrosis (IPF) is a disease of unknown cause in which areas of normal lung tissue are replaced by scars. As a result it becomes harder for the lungs to extract oxygen from the air. IPF is commonly progressive, and around 50% of patients diagnosed with the disease die after approximately 3 years. The most common, troublesome symptoms of IPF are breathlessness on exertion, and cough. No drug treatments have been unequivocally shown to improve the death rate, or to significantly impact upon symptoms, in IPF.
In recent years it has been recognised that cough can be caused by small amounts of liquid coming up from the stomach and "going down the wrong way" into the lungs, a process commonly known as "reflux". As liquid in the stomach is usually acidic, patients' lungs may repeatedly be exposed to small amounts of acid. Reflux is unusually common in IPF and could potentially contribute to the debilitating cough found with the disease. However there are many potential causes for cough in IPF.
Stomach acid can be efficiently "switched off" by drugs called "proton pump inhibitors", one of which is called omeprazole. If reflux of stomach acid does contribute to cough in IPF, omeprazole might be expected to reduce cough. The purpose of this study is therefore to test whether omeprazole does reduce cough in patients with IPF. Sixty patients with IPF will be randomly allocated to have 3 months of omeprazole or a placebo. Neither the patient nor the doctor will be aware which treatment has been given, ie this is a randomised "double-blind", placebo--controlled trial. Patients' cough frequency will be measured before and after treatment and the change in cough frequency compared in those receiving omeprazole and those receiving placebo. Change in cough frequency is the main thing we aim to compare, but a range of other measurements will be assessed such as the numbers of patients eligible to take part, agreeing to randomisation and providing outcome data, patients' lung function, symptom scores, the amount of reflux, and the amount of inflammation in the lungs.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Tyne & Wear
-
Newcastle upon Tyne, Tyne & Wear, United Kingdom, NE1 4LP
- The Newcastle upon Tyne Hospitals NHS Foundation Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- IPF is considered the most likely diagnosis by the Regional Interstitial Lung Disease Multidisciplinary Team meeting (ILD-MDT).
- History of cough, with or without exertional dyspnoea.
- High resolution computed tomography (HRCT) scan features of honeycombing in a predominantly basal subpleural distribution.
- Bibasal crackles on auscultation.
- Features of a restrictive ventilatory defect [vital capacity (VC) <90% predicted and/or diffusion factor for carbon monoxide (Tco) <90% predicted].
- Aged 40-85 years.
- Patients taking short courses (eg. 2 months) of proton pump inhibitors (PPI) will be eligible once the treatment has been discontinued for a minimum of 1 month.
Exclusion Criteria:
- Known allergy to Omeprazole or other proton pump inhibitor.
- Concomitant use of warfarin, diazepam, phenytoin, ketoconazole.
- Concomitant use of a regular PPI, antacid, prokinetic or raft alginate during the trial period.
- History of upper respiratory tract infection, lower respiratory tract infection or exacerbation of IPF in the 4 weeks before starting study drugs.
- Active trial of treatment for IPF 9eg. prednisolone, pirfenidone, N-acetylcysteine) started in the 4 weeks before starting study drugs.
- Documented history of hepatic cirrhosis.
- Pregnancy or lactation.
- ILD-MDT considers the most likely cause of he patient's ILD to be a condition other than IPF (eg. rheumatoid lung, systemic sclerosis ILD, asbestosis, chronic hypersensitivity pneumonitis, sarcoidosis, etc.).
- Concurrent enrolment in a trial of a Clinical Trial of Investigational Medicinal Product (CTIMP) for IPF.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Omeprazole
Omeprazole 20 milligrams twice a day taken for 90 days
|
Drug
Other Names:
|
Placebo Comparator: Matched placebo
Matched placebo twice a day taken for 90 days
|
Matched placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
objectively measured cough frequency
Time Frame: 90 days
|
the change in frequency of objectively measured cough from beginning of the study to the end of treatment (within 2 weeks of completion of treatment).
This will be compared in the two groups.
|
90 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
symptoms of cough
Time Frame: 90 days
|
change in symptoms of cough at the end of treatment as measured by validated cough questionnaire
|
90 days
|
reflux symptoms
Time Frame: 90 days
|
change in symptoms of reflux as measured by validated questionnaires
|
90 days
|
acid and non-acid reflux
Time Frame: 90 days
|
change in acid and non-acid reflux measured by oesophageal physiological study
|
90 days
|
vital capacity (VC) & transfer factor for carbon monoxide (Tco)
Time Frame: 90 days
|
change in VC and Tco as measured by lung function tests
|
90 days
|
6 minute walk distance
Time Frame: 90 days
|
change in 6 minute walk distance from baseline to 90 days
|
90 days
|
assess amount of inflammation in lung
Time Frame: 90 days
|
assess markers of lung inflammation in bronchoalveolar lavage (BAL) fluid (eg.
concentration of transforming growth factor beta, interleukin-8 etc.)
|
90 days
|
lung infection rate
Time Frame: 90 days
|
assess bronchoalveolar lavage (BAL) fluid for infections over period from baseline to 90 days, also patient reported infection in adverse event diary
|
90 days
|
adverse events rate
Time Frame: 90 days
|
patient reported adverse events, assess lung infection rate in bronchoalveolar fluids over period from baseline to 90 days
|
90 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
rate of recruitment
Time Frame: 18 months
|
Number of participants eligible and consented for study
|
18 months
|
rate of study completion
Time Frame: 18 months
|
Number of participants completing all study procedures (over 90 days for each participant)
|
18 months
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: John Simpson, FRCP, Newcastle University
- Principal Investigator: Ian Forrest, MRCP, Newcastle upon Tyne Hospitals NHS Foundation Trust
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IAFIPF001
- 2013-003301-26 (EudraCT Number)
- IPFPSG12-7 (Other Grant/Funding Number: British Lung Foundation)
- 13/YH/0284 (Other Identifier: Research Ethics Committee)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Idiopathic Pulmonary Fibrosis
-
St. Antonius HospitalZonMw: The Netherlands Organisation for Health Research and Development; Boeringer...RecruitingPulmonary Fibrosis Idiopathic FamilialNetherlands
-
Sheba Medical CenterUnknownIDIOPATHIC PULMONARY FIBROSISIsrael
-
Wake Forest University Health SciencesMayo Clinic; The University of Texas Health Science Center at San AntonioCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Theravance BiopharmaTerminatedIdiopathic Pulmonary Fibrosis (IPF)United Kingdom
-
University of California, San FranciscoCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
BiogenCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Liminal BioSciences Ltd.CompletedIdiopathic Pulmonary Fibrosis (IPF)Canada
-
Bristol-Myers SquibbCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Angion Biomedica CorpNot yet recruitingIdiopathic Pulmonary Fibrosis (IPF)
-
Xfibra, Inc.Not yet recruitingIdiopathic Pulmonary Fibrosis (IPF)
Clinical Trials on Omeprazole
-
Damascus HospitalWithdrawnPeptic Ulcer Hemorrhage | Marginal Ulcer | Gastroduodenal UlcerSyrian Arab Republic
-
MetroHealth Medical CenterCompleted
-
University of LouisvilleBausch Health Americas, Inc.CompletedGastroesophageal Reflux Disease | GastroparesisUnited States
-
BayerBausch Health Americas, Inc.CompletedGastric Acid | Human Experimentation
-
BayerBausch Health Americas, Inc.CompletedGastric Acid | Human Experimentation
-
Aboca Spa Societa' AgricolaUniversity of Roma La Sapienza; Doppel Farmaceutici; BMR GenomicsCompleted
-
Yvonne RomeroBausch Health Americas, Inc.CompletedErosive EsophagitisUnited States
-
Nekkar Lab SrlOpera CRO, a TIGERMED Group CompanyRecruitingGastroesophageal Reflux Disease (GERD)Italy, Romania